𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pilot study to evaluate the safety and therapeutic efficacy of topical oxifulvic acid in atopic volunteers

✍ Scribed by J.R. Snyman; J. Dekker; S.C.K. Malfeld; C.E.J. van Rensburg

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
82 KB
Volume
57
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Double-blind, placebo-controlled study t
Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism
✍ Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 66 KB πŸ‘ 1 views

## Abstract Drooling is a frequent symptom in Parkinson's disease (PD), occurring in almost 75% of all patients. Although it is now well known that drooling in PD is the result of swallowing difficulties rather than excessive saliva production, few treatments have been developed to reduce it. Clini

Open-label flexible-dose pilot study to
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
✍ Joseph H. Friedman; Robert M. Berman; Christopher G. Goetz; Stewart A. Factor; W πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 57 KB πŸ‘ 1 views

## Abstract Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstr

A multicentre, randomized, double-blind,
A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study
✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 139 KB πŸ‘ 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre